论文部分内容阅读
非酒精性脂肪性肝病(NAFLD)是MS在肝脏的表现,IR在其发病中起关键作用。法尼酯X受体是调节糖类、脂类代谢和IR的关键因素,6-乙基-鹅去氧胆酸(OCA)作为其选择性激动剂,是NAFLD的潜在治疗药物。多项动物研究结果表明,OCA可改善肝脏脂肪变性,抑制脂质在肝脏堆积,临床试验也证实,其可逆转非酒精性脂肪性肝炎患者的肝脏组织学改变。OCA可能对IR的改善也有一定作用,但长期使用对IS的影响情况还需进一步深入研究。
Non-alcoholic fatty liver disease (NAFLD) is a manifestation of MS in the liver and IR plays a key role in its pathogenesis. Farnesoid X receptor is a key regulator of carbohydrate, lipid metabolism and IR. 6-Ethyl-chenodeoxycholic acid (OCA), as a selective agonist, is a potential therapeutic agent for NAFLD. A number of animal studies have shown that OCA improves hepatic steatosis and inhibits lipid accumulation in the liver and clinical trials also confirm that it reverses liver histology in patients with non-alcoholic steatohepatitis. OCA may also have some effect on the improvement of IR, but the long-term impact on IS needs to be further studied.